| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 332 | 2021 |
| Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations K Rejeski, M Subklewe, M Aljurf, E Bachy, A Balduzzi, P Barba, B Bruno, ... Blood 142 (10), 865-877, 2023 | 154 | 2023 |
| T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals N Philipp, M Kazerani, A Nicholls, B Vick, J Wulf, T Straub, M Scheurer, ... Blood, The Journal of the American Society of Hematology 140 (10), 1104-1118, 2022 | 141 | 2022 |
| The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL K Rejeski, A Perez, G Iacoboni, O Penack, V Bücklein, L Jentzsch, ... Journal for immunotherapy of cancer 10 (5), 2022 | 122 | 2022 |
| SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells Y Liang, T Tebaldi, K Rejeski, P Joshi, G Stefani, A Taylor, Y Song, ... Leukemia 32 (12), 2659-2671, 2018 | 84 | 2018 |
| Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma G Iacoboni, K Rejeski, G Villacampa, JA van Doesum, A Chiappella, ... Blood advances 6 (12), 3606-3610, 2022 | 79 | 2022 |
| Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy G Iacoboni, V Navarro, AÁ Martín-López, K Rejeski, M Kwon, KA Jalowiec, ... Journal of Clinical Oncology 42 (2), 205-217, 2024 | 71 | 2024 |
| The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ... Journal of Hematology & Oncology 16 (1), 88, 2023 | 60 | 2023 |
| Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies E Kampouri, JS Little, K Rejeski, O Manuel, SP Hammond, JA Hill Transplant Infectious Disease 25, e14157, 2023 | 59 | 2023 |
| Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell … K Rejeski, WG Kunz, M Rudelius, V Bücklein, V Blumenberg, C Schmidt, ... BMC infectious diseases 21, 1-8, 2021 | 50 | 2021 |
| A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy DM Cordas dos Santos, T Tix, R Shouval, A Gafter-Gvili, JB Alberge, ... Nature medicine 30 (9), 2667-2678, 2024 | 48 | 2024 |
| Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy K Rejeski, A Burchert, G Iacoboni, P Sesques, L Fransecky, V Bücklein, ... Blood advances 6 (16), 4719-4725, 2022 | 48 | 2022 |
| Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells P Karschnia, KC Miller, AJ Yee, K Rejeski, PC Johnson, N Raje, ... Blood 142 (14), 1243-1248, 2023 | 46 | 2023 |
| An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA K Rejeski, R Greco, F Onida, I Sánchez-Ortega, C Bonini, A Sureda, ... Hemasphere 7 (5), e889, 2023 | 42 | 2023 |
| AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms K Rejeski, J Duque-Afonso, M Lübbert Oncogene 40 (38), 5665-5676, 2021 | 40 | 2021 |
| Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion K Rejeski, A Perez, G Iacoboni, V Blumenberg, VL Bücklein, S Völkl, ... Science Advances 9 (38), eadg3919, 2023 | 37 | 2023 |
| Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells P Karschnia, K Rejeski, M Winkelmann, F Schöberl, VL Bücklein, ... Neurology 98 (21), 884-889, 2022 | 37 | 2022 |
| Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B … DMC Dos Santos, K Rejeski, M Winkelmann, L Liu, P Trinkner, S Günther, ... Haematologica 107 (9), 2096, 2022 | 32 | 2022 |
| Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma K Rejeski, MD Jain, EL Smith Transplantation and Cellular Therapy 29 (7), 418-428, 2023 | 30 | 2023 |
| The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel … K Rejeski, Y Wang, O Albanyan, J Munoz, P Sesques, G Iacoboni, ... American journal of hematology 98 (11), 1699-1710, 2023 | 29 | 2023 |